PASTA

Serial Number 90896969
734

Registration Progress

Application Filed
Aug 23, 2021
Under Examination
Mar 7, 2023
Approved for Publication
Jan 10, 2023
Published for Opposition
Jan 10, 2023
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Mar 07, 2026 48 days
Statement of Use required (all extensions used)

Trademark Image

PASTA

Basic Information

Serial Number
90896969
Filing Date
August 23, 2021
Published for Opposition
January 10, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
734
Status Date
Jan 7, 2026
Application
Pending
Classes
005 042

Rights Holder

Entrada Therapeutics, Inc.

03
Address
One Design Center Pl, Suite 17-500
Boston, MA 02210

Ownership History

Entrada Therapeutics, Inc.

Original Applicant
03
Boston, MA

Entrada Therapeutics, Inc.

Owner at Publication
03
Boston, MA

Legal Representation

Attorney
Stephanie H. Bald

USPTO Deadlines

Next Deadline
48 days remaining
NOA E-Mailed - SOU Required
Due Date
March 07, 2026

Application History

40 events
Date Code Type Description Documents
Jan 8, 2026 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 7, 2026 EX5G S SOU EXTENSION 5 GRANTED Loading...
Aug 19, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Jan 7, 2026 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Aug 20, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 5, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 4, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
Mar 4, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
Mar 4, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 5, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 5, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Sep 5, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Sep 5, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 13, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 12, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
Feb 12, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Feb 12, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 30, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 28, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Aug 28, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 28, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 24, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 24, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 24, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jul 24, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jul 24, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Mar 7, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 10, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 10, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 21, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 2, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 1, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 30, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 30, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 3, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 3, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 3, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 25, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 26, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals for human use, namely, pharmaceutical preparations administered via parenteral injection or infusion for prevention and treatment of inflammatory, autoimmune, genetic, neurological, metabolic, infectious, hematological, musculo-skeletal, degenerative, cardiovascular, respiratory, gastrointestinal, endocrinological, dermatological, genitourinary, ophthalmological, oncological, and nephrological diseases and conditions mediated via intracellular transport processes
Class 042
Pharmaceutical research and development services

Classification

International Classes
005 042